

Dietary Fiber Is Beneficial for the Prevention of Cardiovascular Disease: An Umbrella Review of Meta-analyses



Marc P. McRae, MSc, DC, FACN, DACBN

ABSTRACT

Objective: The purpose of this study was to review previously published meta-analyses on the effectiveness of dietary fiber on cardiovascular disease.

Methods: An umbrella review of all published meta-analyses was performed. A PubMed search from January 1, 1980, to January 31, 2017, was conducted using the following search strategy: (fiber OR glucan OR psyllium OR fructans) AND (meta-analysis OR systematic review). Only English-language publications that provided quantitative statistical analysis on cardiovascular disease, lipid concentrations, or blood pressure were retrieved.

Results: Thirty-one meta-analyses were retrieved for inclusion in this umbrella review, and all meta-analyses comparing highest versus lowest dietary fiber intake reported statistically significant reductions in the relative risk (RR) of cardiovascular disease mortality (RR = 0.77-0.83), as well as the incidences of cardiovascular disease (RR = 0.72-0.91), coronary heart disease (RR = 0.76-0.93), and stroke (RR = 0.83-0.93). Meta-analyses on supplementation studies using β -glucan or psyllium fibers also reported statistically significant reductions in both total serum and low-density lipoprotein cholesterol concentrations.

Conclusion: This review suggests that individuals consuming the highest amounts of dietary fiber intake can significantly reduce their incidence and mortality from cardiovascular disease. Mechanistically, these beneficial effects may be due to dietary fibers' actions on reducing total serum and low-density lipoprotein cholesterol concentrations between 9.3 to 14.7 mg/dL and 10.8 to 13.5 mg/dL, respectively. (*J Chiropr Med* 2017;16:289-299)

Key Indexing Terms: *Dietary Fiber; Meta-analysis; Cardiovascular Diseases; Coronary Heart Disease; Stroke; Cholesterol; Blood Pressure*

INTRODUCTION

In the United States, at least 21% of adults have undesirably high serum cholesterol concentrations of >240 mg/dL, and 28% have hypertension.¹⁻³ Both hypercholesterolemia and hypertension are contributing factors in the development of coronary heart disease and stroke, which together contribute to 38% of all deaths caused by cardiovascular disease in the United States.⁴⁻⁶ Dietary fiber intake has repeatedly been reported to be beneficial in reducing both serum cholesterol and blood pressure, and so it is believed that a deficiency in dietary fiber might be contributing to the epidemic of cardiovascular disease.⁷

Dietary fibers are the edible parts of plants that are resistant to digestion and absorption in the human small intestine, and when comparing persons with the highest dietary fiber intakes with those with the lowest, the relative risk of total all-cause mortality dropped by 16% to 23%.⁸⁻¹⁰

Many past clinical trials investigating dietary fiber intake on cardiovascular disease risk have reported protective benefits,¹¹⁻¹⁴ but not all of these trials are in agreement.¹⁵⁻¹⁸ Many of the clinical trials conducted to study the effects of dietary fiber intake on cardiovascular disease may have had sample sizes that did not provide sufficient statistical power to detect small potentially meaningful changes in effect.¹⁹ Given the inconsistency of the existing literature and the insufficient statistical power as a result of small sample sizes, a pooling of information from individual trials could provide a more precise and accurate estimate of dietary fibers' role in ameliorating cardiovascular disease. To achieve this result, many investigators have turned to performing a powerful statistical method known as meta-analysis. Meta-analyses are fundamental to provide the highest level of evidence to best inform health care decision making. Therefore, the purpose and objective of this paper is to summarize the evidence from

Department of Basic Sciences, National University of Health Sciences, Lombard, Illinois.

Corresponding author: Marc P. McRae, MSc, DC, FACN, DACBN, National University of Health Sciences, 200 E. Roosevelt Rd, Lombard, IL 40148. Tel.: +1 630 889 6592. (e-mail: mmcrae@nuhs.edu).

Paper submitted February 27, 2017; in revised form May 2, 2017; accepted May 23, 2017.

1556-3707

© 2017 National University of Health Sciences.

<https://doi.org/10.1016/j.jcm.2017.05.005>

previously published meta-analyses regarding the effectiveness of the role of dietary fiber as a therapeutic agent for cardiovascular disease.

METHODS

An umbrella review was selected for this study. An umbrella review provides a summary of existing published meta-analyses and systematic reviews and determines whether authors addressing similar review questions independently report similar results and arrive at similar conclusions.²⁰

Because meta-analyses started appearing in the medical literature in the early 1980s, a systematic literature search of PubMed and CINAHL from January 1, 1980, to January 31, 2017, was conducted using the following search strategy: “(fiber OR fibre OR chitosan OR fructan OR glucon OR gums OR inulin OR lignin OR pectin OR psyllium OR bran) AND (meta-analysis OR systematic review).” The titles and abstracts from the literature search were scanned, and only English-language publications that provided quantitative statistical analysis on cardiovascular disease, coronary heart disease, stroke, serum lipids, cholesterol, and blood pressure were retrieved. Meta-analyses or systematic reviews that did not present study-specific summary data using a minimum of 4 randomized controlled trials were excluded.

For the published meta-analyses that were accepted into this review, the following information was extracted and

entered into an Excel spreadsheet: number of publications included in the meta-analysis, number of total participants, fiber type and daily dose, pooled treatment effects for clinical endpoints (such as total cholesterol or systolic blood pressure), and/or summary relative risks (RRs). Although not always present, the meta-analyses were also analyzed for their disclosure of quality assessment, statistical heterogeneity (Cochrane Q test and I^2 statistic), and publication bias (visual inspection of funnel plots and Egger or Begg regression test). A methodological quality appraisal was conducted for all meta-analyses using the Critical Appraisal Checklist for Systematic Reviews, which was developed by the Umbrella Review Methodology Working Group.²⁰ This checklist consists of 10 items; each item within the instrument can receive 1 point, for an overall quality score that could range from 0 to 10. Meta-analyses with quality scores ranging from 0 to 4 were labeled as low quality, those with scores between 5 and 7 as medium quality, and those with scores of 8 to 10 as high quality. Because this is a descriptive summary review of meta-analyses, no statistical analyses were performed.

RESULTS

The initial search strategy identified 516 articles, and after careful review 31 meta-analyses were retrieved for inclusion into this umbrella review.²¹⁻⁵¹ One meta-analysis was excluded because it was not published in English; this




Fig 1. Flow chart of meta-analysis selection.

Table 1. Effect of High vs Low Fiber Intake on the Incidence of Developing Cardiovascular Disease

Meta-analysis Authors, Year	No. of Studies in Meta-analysis	No. of Participants in Meta-analysis	Main Findings of Meta-analysis	<i>Q</i> Test <i>P</i> Value	<i>I</i> ² Statistic	Egger or Begg Test <i>P</i> Value	Quality Assessment and Outcome
Anderson et al, 2000 ^{21, a}	5	136 329	RR = 0.72, <i>P</i> < .05	<i>P</i> < .05			
Ye et al, 2012 ²²	15	846 945	RR = 0.81, <i>P</i> < .05	NS	21%	<i>P</i> = .04	
Threapleton et al, 2013 ²³	10	NR	RR = 0.91, ^b <i>P</i> < .001	NR	45%	NR	NOS 7/10 high quality

NOS, Newcastle-Ottawa scale; NR, not reported; NS, not significant; RR, relative risk.

^a Low-quality score on the Critical Appraisal Checklist for Systematic Reviews.

^b 7 g/d.

meta-analysis investigated the effects of fructans on blood lipid profiles.⁵² A flow chart of the meta-analyses selection process is provided in Figure 1.

In regard to the methodological quality of the 31 meta-analyses in this umbrella review, the mean quality appraisal score was 8 of 10, where 22 meta-analyses (71%) satisfied high-quality scoring between 8 and 10; 6 (19%) satisfied medium-quality scoring between 5 and 7; and 3 (10%) satisfied low-quality scoring, with 1 scoring a 4 and the remaining 2 scoring a 3. These 3 low-quality meta-analyses included the paper by Pereira et al.,²⁴ and both papers by Anderson et al.^{21,44} Although these 3 meta-analyses have been deemed lower quality, they were still included in this umbrella review because they provided useful information regarding the effectiveness of dietary fiber as a therapeutic agent for cardiovascular disease.

The meta-analyses presented in Tables 1 through 4 are based on dietary surveys that compare the highest vs lowest daily dietary fiber consumption. For populations who consumed the highest dietary fiber intake, the incidence of cardiovascular disease was significantly reduced in all 3 meta-analyses, with the relative risk ranging between 0.72 and 0.91 (Table 1). Cardiovascular disease mortality was also significantly reduced in all 5 meta-analyses, with the relative risk ranging between 0.77 and 0.83 (Table 2). The incidence

of coronary heart disease was significantly reduced in all 4 meta-analyses, with the relative risk ranging between 0.76 and 0.93 (Table 3). And finally, the incidence of stroke was significantly reduced in all 3 meta-analyses, with the relative risk ranging between 0.83 and 0.93 (Table 4).

The meta-analyses presented in Tables 5 and 6 are based on clinical trials using fiber supplementation to determine if such interventions would result in physiological changes associated with cardiovascular disease (such as decreases in serum lipids and blood pressure). Table 5 shows that fiber supplementation, regardless of the type of fiber, significantly reduced total serum cholesterol in 13 of 14 meta-analyses, and low-density lipoprotein (LDL) cholesterol in 14 of 15 meta-analyses. More specifically, the 9 meta-analyses involving dietary supplementation with β-glucan and the 3 meta-analyses involving psyllium supplementation all reported significant reductions for both total serum cholesterol and LDL cholesterol. There were 2 meta-analyses using fructan supplementation with 1 reporting only a significant decrease in triglycerides (↓ 15.1 mg/dL), whereas the second reported no significant change in triglycerides (↓ 1.8 mg/dL) but a significant decrease in LDL cholesterol. Finally, the meta-analysis using chitosan supplementation reported a significant reduction in total cholesterol but not LDL cholesterol. However, there was

Table 2. Effect of High vs Low Fiber Intake on Cardiovascular Disease Mortality

Meta-analysis Authors, Year	No. of Studies in Meta-analysis	No. of Participants in Meta-analysis	Main Findings of Meta-analysis	<i>Q</i> Test <i>P</i> Value	<i>I</i> ² Statistic	Egger or Begg Test <i>P</i> Value	Quality Assessment and Outcome
Pereira et al, 2004 ^{24, a}	10	336 244	RR = 0.81, ^b <i>P</i> < .001	NS	NR		
Wu et al, 2014 ²⁵	15	496 858	RR = 0.83, <i>P</i> < .001	NS	0%	NS	NOS 12/15 high quality
Liu et al, 2015 ²⁶	16	340 830	HR = 0.77, <i>P</i> < .05	NS	25%	NS	
Kim and Je, 2016 ²⁷	7	627 651	RR = 0.77, <i>P</i> < .05	NS	13%	NS	3/7 high quality
Hajishafiee et al, 2016 ²⁸	10	842 172	RR = 0.82, <i>P</i> < .05	NS	0%	NS	NOS 8/10 high quality

HR, hazard ratio; NOS, Newcastle-Ottawa scale; NR, not reported; NS, not significant; RR, relative risk.

^a Low-quality score on the Critical Appraisal Checklist for Systematic Reviews.

^b 10 g/d.

Table 3. Effect of High vs Low Fiber Intake on the Incidence of Developing Coronary Heart Disease

Meta-analysis Authors, Year	No. of Studies in Meta-analysis	No. of Participants in Meta-analysis	Main Findings of Meta-analysis	Q Test P Value	I ² Statistic	Egger or Begg Test P Value	Quality Assessment and Outcome
Pereira et al, 2004 ^{24, a}	9	306 064	RR = 0.91, ^b P = .005	NS	NR		
Threapleton et al, 2013 ²³	12	NR	RR = 0.91, ^c P < .001	NS	33%	NR	NOS 10/12 high quality
Wu et al, 2014 ²⁵	16	561 756	RR = 0.93, P < .001	NS	0%	NS	NOS 13/16 high quality
Kim and Je, 2016 ²⁷	8	500 672	RR = 0.76, P < .05	NS	40%	NS	4/8 high quality

NOS, Newcastle-Ottawa scale; NR, not reported; NS, not significant; RR, relative risk.

^a Low-quality score on the Critical Appraisal Checklist for Systematic Reviews.

^b 10 g/d.

^c 7 g/d.

statistically significant heterogeneity and publication bias associated with this observation.

In regard to magnitude of change, β-glucan supplementation resulted in total serum cholesterol reductions ranging between 5.1 to 23.2 mg/dL and LDL cholesterol reductions ranging between 7.3 to 25.5 mg/dL. Psyllium supplementation resulted in total serum cholesterol reductions ranging between 9.3 to 14.7 mg/dL and LDL cholesterol reductions ranging between 10.8 to 13.5 mg/dL. Figure 2 shows the frequency of observed reductions with β-glucan and psyllium combined for both total serum cholesterol and LDL cholesterol, respectively. Statistically significant heterogeneity was observed in 2 of the 9 β-glucan meta-analyses for both total serum and LDL cholesterol. The 1 psyllium meta-analysis that tested for heterogeneity reported this to be statistically significant for total serum cholesterol but not for LDL cholesterol. Only 7 of the 9 β-glucan meta-analyses tested for publication bias, and 3 of the 7 noted this to be statistically significant. Only 1 of the 3 psyllium meta-analyses tested for publication bias and reported it to be statistically significant for only LDL cholesterol.

The meta-analyses presented in Table 6 indicate that dietary fiber intake resulted in nonsignificant reductions in systolic blood pressure for all 4 meta-analyses, and only 2 of the 4 meta-analyses reported significant reductions in diastolic blood pressure. The magnitude of change in diastolic blood pressure for these 2 meta-analyses was 1.65 and 1.77 mmHg, but the former also noted statistically significant

heterogeneity. The overall range in systolic and diastolic blood pressure reduction for all 4 meta-analyses was 0.92 to 1.92 mmHg and 0.71 to 1.77 mmHg, respectively.

DISCUSSION

Based on the relative risks obtained from the meta-analyses in this umbrella review, it is apparent that individuals consuming the highest amounts of dietary fiber can reduce their chances of developing coronary heart disease and stroke by somewhere between 7% to 24%, as well as reducing their overall morbidity and mortality brought on by cardiovascular disease by 17% to 28%. A greater intake of dietary fiber may reduce the risk of developing cardiovascular disease through a variety of mechanisms, such as improving serum lipid concentrations, lowering blood pressure, and reducing inflammation (Fig 3).

In regard to promoting healthy serum lipids, it appears that both β-glucan and psyllium fiber supplementation significantly reduce total serum and LDL cholesterol concentrations. β-glucan is a water-soluble and fermentable dietary fiber that is derived from oats and barley, and psyllium is a water-soluble, gel-forming mucilaginous functional fiber derived from the seed husk of *Plantago ovata*. Based on the 12 meta-analyses investigating supplementation of either β-glucan or psyllium fibers, the most common reductions in total serum cholesterol and LDL cholesterol ranged somewhere between 9 and 12 mg/dL

Table 4. Effect of High vs Low Fiber Intake on the Incidence of Having a Stroke

Meta-analysis Authors, Year	No. of Studies in Meta-analysis	No. of Participants in Meta-analysis	Main Findings of Meta-analysis	Q Test P Value	I ² Statistic	Egger or Begg Test P Value	Quality Assessment and Outcome
Zhang et al, 2013 ²⁹	11	325 627	RR = 0.83, P < .05	NS	39%	NS	NOS 9/11 high quality
Chen et al, 2013 ³⁰	6	314 864	RR = 0.87, P < .05	NS	36%	NS	NOS 6/6 high quality
Threapleton et al, 2013 ³¹	7	488 982	RR = 0.93, ^a P < .05	P < .05	59%	P = .002	

NOS, Newcastle-Ottawa scale; NS, not significant; RR, relative risk.

^a 7 g/d.

(Fig 2). This modest reduction is clinically significant in light of the fact that a 12 mg/dL reduction in total cholesterol can potentially translate to a 10% to 20% reduction in the risk for developing cardiovascular disease.⁵³ However, clinical certainty of this finding is tentative because of the fact that 3 of these 10 meta-analyses using β -glucan or psyllium fibers reported statistically significant heterogeneity, and 4 of the 8 meta-analyses reported statistically significant publication bias. Ideally, the studies combined into any meta-analysis should all have the same experimental protocols; however, increased heterogeneity is inevitable because of the wide variation in study design. Differences in study design include the number of participants; duration of the study; age, sex, body mass index, and total energy intake for the participants; and dose and form of the dietary fiber used in the study. In regard to publication bias, published studies are more likely than unpublished ones to report positive research outcomes, and this can potentially bias the results of the meta-analysis as the effect size of the weighted average of the meta-analysis is overestimated.

Mechanistically, the beneficial effects on reducing total serum cholesterol are attributed to soluble fiber's ability to chelate cholesterol in the lumen of the small intestine and therefore reduced the absorption of cholesterol. Soluble fiber also increases the fecal excretion of bile acids, and this diverts hepatic cholesterol for bile acid production, thus lowering circulating levels of plasma LDL cholesterol as it is taken up by the liver from the plasma to replenish cholesterol levels. Also, the fibers that are freely fermentable by the colonic bacteria are converted into short chain fatty acids such as acetic, propionic, and butyric acids. Propionic acid can be absorbed and inhibit the liver's rate-limiting cholesterol synthesis enzyme HMG-CoA reductase.⁵⁴

Although 1 of the 6 meta-analyses using β -glucan fibers reported a significant reduction in triglyceride concentration, overall there does not appear to be any significant benefit with any fiber type for clinically relevant changes in high-density lipoprotein (HDL) cholesterol and/or triglyceride concentrations.

Of the 4 meta-analyses that investigated dietary fiber's effects on blood pressure, none of them reported any statistically significant reductions in systolic blood pressure, but 2 meta-analyses did report statistically significant reductions in diastolic blood pressure. These significant reductions in diastolic blood pressure of 1.65 and 1.77 mm Hg could potentially translate to a reduction in developing cardiovascular disease of up to 7%, but this potential may be called into question because of the significant heterogeneity reported in the 1 of these 2 meta-analyses.⁵⁵ In regard to mechanism of action, dietary fiber forms gels in the stomach and small intestine, slowing the rate of glucose absorption, and this inhibits a postprandial rise of glucose concentrations, which can improve insulin sensitivity by decreasing insulin secretion. It has been documented that hyperinsulinemia plays a mechanistic role in the development of hypertension.⁵⁶ It is also possible that small

decreases in blood pressure may be due solely to the fact that diets high in fiber may also provide higher amounts of potassium and magnesium, both of which are known to have small effects on reducing blood pressure.^{57,58}

Because inflammation plays a direct role in the pathophysiology of cardiovascular disease, it is important to note that dietary fiber intake has been reported to be inversely associated with inflammatory markers that are central in the initiation and progression of cardiovascular disease.⁵⁹ Although the mechanisms underlying the association between dietary fiber and inflammation are still unclear, it appears that a diet rich in dietary fibers will also provide a high concentration of phytochemicals, such as polyphenols, and it is possible that these polyphenols can inhibit the transcriptional activity of the proinflammatory transcription factor nuclear factor- κ B.⁶⁰ Inhibition of nuclear factor- κ B by dietary fiber is best revealed through the reduction of inflammatory markers such as C-reactive protein, tumor necrosis factor α , and interleukin 6.⁶¹⁻⁶³ Also, the increased intake of fiber replaces the consumption of other potentially detrimental foods such as saturated fats and sugars.

This umbrella review did not thoroughly investigate the differential effects the various different dietary forms of fiber could have on cardiovascular disease (soluble vs insoluble fibers or cereal vs fruit vs vegetable fibers), because only a small number of meta-analyses have undertaken subgroup analyses to investigate these potential differences. In regard to soluble vs insoluble fiber's actions on cardiovascular mortality, coronary heart disease incidence, and stroke incidence, there was no difference between the highest and lowest groups for both soluble and insoluble fibers.^{25,27,29} In regard to cereal vs fruit and vegetable fiber subgroups, both cereal and fruit fibers performed better than vegetable fibers in reducing cardiovascular mortality.^{24,25,27}

The Dietary Guidelines for Americans state that the adequate intake value of dietary fiber consumption is 25 to 38 g/d, but the 2009-2010 National Health and Nutrition Examination Survey reported that the daily intake of fiber in the United States is only 17 g/d.⁶⁴ Therefore, emphasizing fiber consumption for health promotion and disease prevention is a critical public health goal, and aggressively promoting the Dietary Guidelines for Americans recommendations of at least 25 to 38 g/d of total dietary fiber may prevent a significant number of chronic diseases (beyond the benefits for cardiovascular disease, dietary fiber may also significantly reduce the incidence of type 2 diabetes and some cancers).^{26,65} However, although the evidence in this umbrella review supports the beneficial association of dietary fiber on cardiovascular risk, there are still too few long-term, large-population randomized controlled trials that have undertaken the goal of analyzing this potentially causal relationship between dietary fiber and cardiovascular disease. Finally, although no tolerable upper limit has been established for total fiber intake, it should be noted that

Table 5. Effects of Increased Fiber Intake on Serum Lipids Levels

Meta-analysis Authors, Year	No. of Studies in Meta-analysis	No. of Participants in Meta-analysis	Fiber Type (Average Amount per Day)	Mean Duration (wk)	Main Findings of Meta-analysis	Q Test P Value	I ² Statistic	Egger or Begg Test P Value	Quality Assessment and Outcome
Brown et al, 1999 ³²	66	2975	Dietary fiber (9.5 g)	7	TC ↓ 10.4 mg/dL, <i>P</i> < .05 LDL ↓ 10.8 mg/dL, <i>P</i> < .05 HDL ↓ 0.8 mg/dL, NS Trigs 0.9 mg/dL, NS	<i>P</i> < .001 <i>P</i> < .001 <i>P</i> < .001 <i>P</i> < .001			
Hartley et al, 2016 ³³	17	1067	Dietary fiber (NR)	12	TC ↓ 7.7 mg/dL, <i>P</i> = .005 LDL ↓ 5.4 mg/dL, <i>P</i> = .001 HDL ↓ 1.2 mg/dL, NS Trigs 0.0 mg/dL, NS	<i>P</i> < .05 NS NS NS	46% 36% 0% 32%		Cochrane 10/17
Ripsin et al, 1992 ³⁴	12	1603	β-Glucan (4 g)	6	TC ↓ 5.1 mg/dL, <i>P</i> < .05 LDL NR HDL NR Trigs NR	NS			
Talati et al, 2009 ³⁵	8	391	β-Glucan (6.5 g)	5	TC ↓ 13.4 mg/dL, <i>P</i> < .05 LDL ↓ 10.0 mg/dL, <i>P</i> < .05 HDL 1.0 mg/dL, NS Trigs ↓ 11.8 mg/dL, <i>P</i> < .05	NS NS NS NS	0% 0% 0% 0%	<i>P</i> = .02 NS NS NS	
AbuMweis et al, 2010 ³⁶	11	329	β-Glucan (6 g)	5	TC ↓ 11.6 mg/dL, <i>P</i> < .000 LDL ↓ 10.4 mg/dL, <i>P</i> < .000 HDL 0.0 mg/dL, NS Trigs ↓ 4.4 mg/dL, NS	NS NS NS NS	16% 0% 30% 41%	<i>P</i> < .05 <i>P</i> < .05 NR NR	Yes, 1 study excluded
Tiwari and Cummins, 2011 ³⁷	11	516	β-Glucan (5 g)	6	TC ↓ 23.2 mg/dL, <i>P</i> < .05 LDL ↓ 25.5 mg/dL, <i>P</i> < .05 HDL 1.2 mg/dL, NS Trigs ↓ 3.5 mg/dL, NS	<i>P</i> < .000 <i>P</i> < .000 NS NS	77% 84% 0% 0%	NS NS NS NS	
Whitehead et al, 2014 ³⁸	28	2519	β-Glucan (5.5 g)	6	TC ↓ 11.2 mg/dL, <i>P</i> < .05 LDL ↓ 11.2 mg/dL, <i>P</i> < .05 HDL 1.1 mg/dL, NS Trigs ↓ 2.0 mg/dL, NS	NS NS <i>P</i> < .001 NS	28% 22% 81% 0%	<i>P</i> < .05 NS NR NR	Yes NR
Zhu et al, 2015 ³⁹	17	916	β-Glucan (5.5 g)	7	TC ↓ 10.1 mg/dL, <i>P</i> < .000 LDL ↓ 8.1 mg/dL, <i>P</i> < .000 HDL ↓ 0.8 mg/dL, NS Trigs ↓ 1.8 mg/dL, NS	NS NS NS NS	0% 0% 0% 0%	NS NS NS NS	Jadad Scale 11/17 high quality

Hou et al, 2015 ⁴⁰	7	453	β-Glucan (NR)	NR	TC ↓ 18.9 mg/dL, <i>P</i> < .05 LDL ↓ 11.2 mg/dL, <i>P</i> < .05 HDL ↓ 1.9 mg/dL, NS Trigs ↓ 14.2 mg/dL, NS	<i>P</i> = .016 NS NS NS	62% 21% 0% 10%		NOS scale 4/7 high quality
Ho et al, 2016 ⁴¹	14	723	β-Glucan from barley (6 g)	5	TC NR LDL ↓ 9.7 mg/dL, <i>P</i> < .000 HDL NR Trigs NR	NS	0%	NS	MQS 7/14 high quality
Ho et al, 2016 ⁴²	56	3745	β-Glucan from oats (4 g)	6	TC NR LDL ↓ 7.3 mg/dL, <i>P</i> < .000 HDL NR Trigs NR	<i>P</i> < .000	79%	NS	MQS 9/56 high quality
Olson et al, 1997 ⁴³	12	404	Psyllium (9 g)	6	TC ↓ 12.0 mg/dL, <i>P</i> < .000 LDL ↓ 13.5 mg/dL, <i>P</i> < .000 HDL 0.0 mg/dL, NS Trigs NR				
Anderson et al, 2000 ^{44, a}	8	656	Psyllium (10 g)	10	TC ↓ 9.3 mg/dL, <i>P</i> < .000 LDL ↓ 10.8 mg/dL, <i>P</i> < .000 HDL ↓ 0.4 mg/dL, NS Trigs ↓ 5.3 mg/dL, NS				
Wei et al, 2009 ⁴⁵	21	1717	Psyllium (10 g)	8	TC ↓ 14.7 mg/dL, <i>P</i> < .05 LDL ↓ 10.8 mg/dL, <i>P</i> < .05 HDL ↓ 1.2 mg/dL, NS Trigs 0.9 mg/dL, NS	<i>P</i> < .000 NS NS NS		NS <i>P</i> = .04 NR NR	
Brighenti, 2007 ⁴⁶	16	290	Fructans (14 g)	5	TC NR LDL NR HDL NR Trigs ↓ 15.1 mg/dL, <i>P</i> = .04	NS	0%	NS	
Liu et al, 2016 ⁴⁷	19	585	Fructans (13 g)	5	TC ↓ 1.5 mg/dL, NS LDL ↓ 5.8 mg/dL, <i>P</i> = .03 HDL 1.2 mg/dL, NS Trigs ↓ 1.8 mg/dL, NS	NS <i>P</i> = .04 NS NS	2% 40% 0% 0%	NS NS NS NS	Cochrane 6/19 high quality
Baker et al, 2009 ⁴⁸	6	416	Chitosan (2.4 g)	9	TC ↓ 11.6 mg/dL, <i>P</i> = .02 LDL ↓ 3.7 mg/dL, NS HDL 1.0 mg/dL, NS Trigs ↓ 4.3 mg/dL, NS	<i>P</i> < .05 NS NS NS	70% 0% 26% 0%	<i>P</i> < .05 <i>P</i> < .05 <i>P</i> < .05 <i>P</i> < .05	

HDL, high-density cholesterol lipoproteins; *LDL*, low-density lipoproteins; *MQS*, methodological quality score; *NR*, not reported; *NS*, not significant; *TC*, total cholesterol; *Trigs*, triglycerides.

^a Low-quality score on the Critical Appraisal Checklist for Systematic Reviews.

Table 6. Effects of Increased Fiber Intake on Blood Pressure

Meta-analysis Authors, Year	No. of Studies in Meta-analysis	No. of Participants in Meta-analysis	Fiber Dose (Average Amount per Day)	Mean Duration (wks)	Main Findings of Meta-analysis	<i>Q</i> Test <i>P</i> Value	<i>I</i> ² Statistic	Egger or Begg Test <i>P</i> Value	Quality Assessment and Outcome
Streppel et al, 2005 ⁴⁹	24	1404	11.5 g	9	SBP ↓ 1.13 mmHg, NS DBP ↓ 1.26 mmHg, NS				Yes NR
Whelton et al, 2005 ⁵⁰	21	1477	11 g	8	SBP ↓ 1.15 mmHg, NS DBP ↓ 1.65 mmHg, <i>P</i> < .005	<i>P</i> < .05 <i>P</i> < .05	NR NR	NS NS	
Evans et al, 2015 ⁵¹	18	1333	6 g	NR	SBP ↓ 0.92 mm Hg, NS DBP ↓ 0.71 mm Hg, NS	<i>P</i> = .023 <i>P</i> = .001	43% 58%	NS NS	Cochrane NR
Hartley et al, 2016 ³³	10	661	NR	12	SBP ↓ 1.92 mm Hg, NS DBP ↓ 1.77 mm Hg, <i>P</i> = .000	<i>P</i> = .001 NS	69% 7%		

DBP, diastolic blood pressure; NR, not reported; NS, not significant; SBP, systolic blood pressure.

minor side effects have been reported, such as flatulence, abdominal bloating, loose stools or diarrhea, and abdominal cramping.⁶⁶

Limitations

This umbrella review has several limitations that should be acknowledged. First, confounding factors are always a potential threat to the validity of any meta-analysis. For instance, people with high dietary fiber intake tend to have other healthy behaviors such as being physically active and avoiding smoking and excessive alcohol intake. Fortunately, the majority of studies included in the meta-analyses that were involved in this umbrella review did adjust for potential confounding factors, but the possibility of residual confounders cannot be excluded. Second, self-reported dietary fiber intake is most often assessed using food frequency questionnaires, and because these dietary assessment tools

were not specifically developed for dietary fiber intake, misclassifications and measurement errors regarding fiber doses and types are quite likely. This problem may also be compounded by the fact that dietary fiber may be defined differently by the various food frequency questionnaire databases in use.⁶⁶ A third limitation is that the meta-analyses reviewed here represent a heterogeneous group of clinical studies composed from a diverse group of participants of different ages, genders, races, and ethnic groups, and therefore readers are cautioned against specifying these results to any one specific sociodemographic group. Finally, as in all literature reviews, the quality of this umbrella review is directly related to the quality of the included meta-analyses, which are dependent on the design and reporting quality of the individual meta-analysis itself, as well as on the quality of the individual studies used to conduct the meta-analysis. Fortunately, the majority (90%) of the meta-analyses in this umbrella review were appraised as having moderate to high methodological quality.




Fig 2. Observed frequencies in the reduction of total serum cholesterol (black bars) and low-density lipoprotein cholesterol (gray bars) from the meta-analyses on β-glucan and psyllium supplementation.

CONCLUSION

The meta-analyses in this umbrella review indicate that individuals consuming the highest amounts of dietary fiber intake can significantly reduce their incidence of and mortality from cardiovascular disease. Mechanistically, these beneficial effects may be due to dietary fibers’ actions on reducing total serum and LDL cholesterol concentrations, and these outcomes are most notable in particular with water-soluble, gel-forming dietary fibers such as β-glucan at 6 g/d or psyllium at 10 g/d.

FUNDING SOURCES AND CONFLICTS OF INTEREST

No funding sources or conflicts of interest were reported for this study.




Fig 3. Proposed mechanisms underlying the observed association between individuals with the highest dietary intakes of fiber and their reduced rates in cardiovascular disease incidence and mortality. CRP, C-reactive protein; IL-6, interleukin 6; LDL, low-density lipoprotein; NF-κB, nuclear factor-κB; TNF-α, tumor necrosis factor α.

CONTRIBUTORSHIP INFORMATION

Concept development (provided idea for the research):
M.P.M.

Design (planned the methods to generate the results):
M.P.M.

Supervision (provided oversight, responsible for organization and implementation, writing of the manuscript):
M.P.M.

Data collection/processing (responsible for experiments, patient management, organization, or reporting data):
M.P.M.

Analysis/interpretation (responsible for statistical analysis, evaluation, and presentation of the results):
M.P.M.

Literature search (performed the literature search):
M.P.M.

Writing (responsible for writing a substantive part of the manuscript): M.P.M.

Critical review (revised manuscript for intellectual content, this does not relate to spelling and grammar checking): M.P.M.

Practical Applications

- Dietary fiber consumption has been postulated to reduce the incidence of cardiovascular disease through reductions in total serum cholesterol and blood pressure.
- Unfortunately, there is much discrepancy when it comes to randomized controlled studies on dietary fiber's effects on these important clinical conditions.
- By combining the meta-analyses on these clinical outcomes as an umbrella review, we can report that increased dietary fiber intake does appear to be beneficial in the prevention of cardiovascular disease.

REFERENCES

1. Carroll MD, Kit BK, Lacher DA, Shero ST, Mussolino ME. Trends in lipids and lipoproteins in US adults, 1988-2010. *JAMA*. 2012;308(15):1545-1554.
2. Kuklina EV, Yoon PW, Keenan NL. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006. *JAMA*. 2009;302(19):2104-2110.
3. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. *JAMA*. 2010;303(20):2043-2050.
4. Amarenco P, Goldstein LB, Messig M, et al. Relative and cumulative effects of lipid and blood pressure control in the stroke prevention by aggressive reduction in cholesterol levels trial. *Stroke*. 2009;40(7):2486-2492.
5. Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. *JAMA*. 2003;290(7):891-897.
6. Murray CJ, Kulkarni SC, Ezzati M. Understanding the coronary heart disease versus total cardiovascular mortality paradox: a method to enhance the comparability of cardiovascular death statistics in the United States. *Circulation*. 2006;113(17):2071-2081.
7. Sánchez-Muniz FJ. Dietary fibre and cardiovascular health. *Nutr Hosp*. 2012;27(1):31-45.
8. Kim Y, Je Y. Dietary fiber intake and total mortality: a meta-analysis of prospective cohort studies. *Am J Epidemiol*. 2014;180(6):565-573.
9. Yang Y, Zhao LG, Wu QJ, Ma X, Xiang YB. Association between dietary fiber and lower risk of all-cause mortality: a meta-analysis of cohort studies. *Am J Epidemiol*. 2015;181(2):83-91.
10. Huang T, Xu M, Lee A, Cho S, Qi L. Consumption of whole grains and cereal fiber and total and cause-specific mortality: prospective analysis of 367,442 individuals. *BMC Med*. 2015;13:59.
11. Streppel MT, Ocké MC, Boshuizen HC, Kok FJ, Kromhout D. Dietary fiber intake in relation to coronary heart disease and all-cause mortality over 40 y: the Zutphen Study. *Am J Clin Nutr*. 2008;88(4):1119-1125.
12. Kokubo Y, Iso H, Saito I, et al. Dietary fiber intake and risk of cardiovascular disease in the Japanese population: the Japan Public Health Center-based study cohort. *Eur J Clin Nutr*. 2011;65(11):1233-1241.
13. Eshak ES, Iso H, Date C, et al. Dietary fiber intake is associated with reduced risk of mortality from cardiovascular disease among Japanese men and women. *J Nutr*. 2010;140(8):1445-1453.
14. Buil-Cosiales P, Zazpe I, Toledo E, et al. Fiber intake and all-cause mortality in the Prevención con Dieta Mediterránea (PREDIMED) study. *Am J Clin Nutr*. 2014;100(6):1498-1507.
15. Ibrügger S, Kristensen M, Poulsen MW, et al. Extracted oat and barley β -glucans do not affect cholesterol metabolism in young healthy adults. *J Nutr*. 2013;143(10):1579-1585.
16. Keogh GF, Cooper GJ, Mulvey TB, et al. Randomized controlled crossover study of the effect of a highly beta-glucan-enriched barley on cardiovascular disease risk factors in mildly hypercholesterolemic men. *Am J Clin Nutr*. 2003;78(4):711-718.
17. Larsson SC, Männistö S, Virtanen MJ, Kontto J, Albanes D, Virtamo J. Dietary fiber and fiber-rich food intake in relation to risk of stroke in male smokers. *Eur J Clin Nutr*. 2009;63(8):1016-1024.
18. Threapleton DE, Greenwood DC, Burley VJ, Aldwairji M, Cade JE. Dietary fibre and cardiovascular disease mortality in the UK Women's Cohort Study. *Eur J Epidemiol*. 2013;28(4):335-346.
19. Thies F, Masson LF, Boffetta P, Kris-Etherton P. Oats and CVD risk markers: a systematic literature review. *Br J Nutr*. 2014;112(suppl 2):S19-S30.
20. Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. *Int J Evid Based Healthc*. 2015;13(3):132-140.
21. Anderson JW, Hanna TJ, Peng X, Kryscio RJ. Whole grain foods and heart disease risk. *J Am Coll Nutr*. 2000;19(3 Suppl):291S-299S.
22. Ye EQ, Chacko SA, Chou EL, Kugizaki M, Liu S. Greater whole-grain intake is associated with lower risk of type 2 diabetes, cardiovascular disease, and weight gain. *J Nutr*. 2012;142(7):1304-1313.
23. Threapleton DE, Greenwood DC, Evans CE, et al. Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis. *BMJ*. 2013;347:f6879.
24. Pereira MA, O'Reilly E, Augustsson K, et al. Dietary fiber and risk of coronary heart disease: a pooled analysis of cohort studies. *Arch Intern Med*. 2004;164(4):370-376.
25. Wu Y, Qian Y, Pan Y, et al. Association between dietary fiber intake and risk of coronary heart disease: a meta-analysis. *Clin Nutr*. 2015;34(4):603-611.
26. Liu L, Wang S, Liu J. Fiber consumption and all-cause, cardiovascular, and cancer mortalities: a systematic review and meta-analysis of cohort studies. *Mol Nutr Food Res*. 2015;59(1):139-146.
27. Kim Y, Je Y. Dietary fibre intake and mortality from cardiovascular disease and all cancers: a meta-analysis of prospective cohort studies. *Arch Cardiovasc Dis*. 2016;109(1):39-54.
28. Hajishafiee M, Saneei P, Benisi-Kohansal S, Esmailzadeh A. Cereal fibre intake and risk of mortality from all causes, CVD, cancer and inflammatory diseases: a systematic review and meta-analysis of prospective cohort studies. *Br J Nutr*. 2016;116(2):343-352.
29. Zhang Z, Xu G, Liu D, Zhu W, Fan X, Liu X. Dietary fiber consumption and risk of stroke. *Epidemiol*. 2013;28(2):119-130.
30. Chen GC, Lv DB, Pang Z, Dong JY, Liu QF. Dietary fiber intake and stroke risk: a meta-analysis of prospective cohort studies. *Eur J Clin Nutr*. 2013;67(1):96-100.
31. Threapleton DE, Greenwood DC, Evans CE, et al. Dietary fiber intake and risk of first stroke: a systematic review and meta-analysis. *Stroke*. 2013;44(5):1360-1368.
32. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. *Am J Clin Nutr*. 1999;69(1):30-42.
33. Hartley L, May MD, Loveman E, Colquitt JL, Rees K. Dietary fibre for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev*. 2016;1:CD011472.
34. Ripsin CM, Keenan JM, Jacobs Jr DR, et al. Oat products and lipid lowering. A meta-analysis. *JAMA*. 1992;267(24):3317-3325.
35. Talati R, Baker WL, Pablonia MS, White CM, Coleman CI. The effects of barley-derived soluble fiber on serum lipids. *Ann Fam Med*. 2009;7(2):157-163.
36. AbuMweis SS, Jew S, Ames NP. β -glucan from barley and its lipid-lowering capacity: a meta-analysis of randomized, controlled trials. *Eur J Clin Nutr*. 2010;64(12):1472-1480.
37. Tiwari U, Cummins E. Meta-analysis of the effect of β -glucan intake on blood cholesterol and glucose levels. *Nutrition*. 2011;27(10):1008-1016.
38. Whitehead A, Beck EJ, Tosh S, Wolever TM. Cholesterol-lowering effects of oat β -glucan: a meta-analysis of

- randomized controlled trials. *Am J Clin Nutr.* 2014;100(6):1413-1421.
39. Zhu X, Sun X, Wang M, et al. Quantitative assessment of the effects of beta-glucan consumption on serum lipid profile and glucose level in hypercholesterolemic subjects. *Nutr Metab Cardiovasc Dis.* 2015;25(8):714-723.
 40. Hou Q, Li Y, Li L, et al. The metabolic effects of oats intake in patients with type 2 diabetes: a systematic review and meta-analysis. *Nutrients.* 2015;7(12):10369-10387.
 41. Ho HV, Sievenpiper JL, Zurbau A, et al. A systematic review and meta-analysis of randomized controlled trials of the effect of barley β -glucan on LDL-C, non-HDL-C and apoB for cardiovascular disease risk reduction. *Eur J Clin Nutr.* 2016;70(11):1340.
 42. Ho HV, Sievenpiper JL, Zurbau A, et al. The effect of oat β -glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials. *Br J Nutr.* 2016;116(8):1369-1382.
 43. Olson BH, Anderson SM, Becker MP, et al. Psyllium-enriched cereals lower blood total cholesterol and LDL cholesterol, but not HDL cholesterol, in hypercholesterolemic adults: results of a meta-analysis. *J Nutr.* 1997;127(10):1973-1980.
 44. Anderson JW, Allgood LD, Lawrence A, et al. Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials. *Am J Clin Nutr.* 2000;71(2):472-479.
 45. Wei ZH, Wang H, Chen XY, et al. Time- and dose-dependent effect of psyllium on serum lipids in mild-to-moderate hypercholesterolemia: a meta-analysis of controlled clinical trials. *Eur J Clin Nutr.* 2009;63(7):821-827.
 46. Brighenti F. Dietary fructans and serum triacylglycerols: a meta-analysis of randomized controlled trials. *J Nutr.* 2007;137(11 Suppl):2552S-2556S.
 47. Liu F, Prabhakar M, Ju J, Long H, Zhou HW. Effect of inulin-type fructans on blood lipid profile and glucose level: a systematic review and meta-analysis of randomized controlled trials. *Eur J Clin Nutr.* 2017;71(1):9-20.
 48. Baker WL, Tercius A, Anglade M, White CM, Coleman CI. A meta-analysis evaluating the impact of chitosan on serum lipids in hypercholesterolemic patients. *Ann Nutr Metab.* 2009;55(4):368-374.
 49. Streppel MT, Arends LR, van't Veer P, Grobbee DE, Geleijnse JM. Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. *Arch Intern Med.* 2005;165(2):150-156.
 50. Whelton SP, Hyre AD, Pedersen B, Yi Y, Whelton PK, He J. Effect of dietary fiber intake on blood pressure: a meta-analysis of randomized, controlled clinical trials. *J Hypertens.* 2005;23(3):475-481.
 51. Evans CE, Greenwood DC, Threapleton DE, et al. Effects of dietary fibre type on blood pressure: a systematic review and meta-analysis of randomized controlled trials of healthy individuals. *J Hypertens.* 2015;33(5):897-911.
 52. Wu T, Yank Y, Zhang L, Han J. Systematic review of the effects of inulin-type fructans on blood lipid profiles: a meta-analysis. *Wei Sheng Yan Jiu.* 2010;39(2):172-176.
 53. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? *BMJ.* 1994;308(6925):367-372.
 54. Bernstein AM, Titgemeier B, Kirkpatrick K, Golubic M, Roizen MF. Major cereal grain fibers and psyllium in relation to cardiovascular health. *Nutrients.* 2013;5(5):1471-1487.
 55. Sesso HD, Stampfer MJ, Rosner B, et al. Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in men. *Hypertension.* 2000;36(5):801-807.
 56. Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Järvinen H. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). *Hypertension.* 1997;30(5):1144-1149.
 57. Zhang X, Li Y, Del Gobbo LC, et al. Effects of magnesium supplementation on blood pressure: a meta-analysis of randomized double-blind placebo-controlled trials. *Hypertension.* 2016;68(2):324-333.
 58. Dickinson HO, Nicolson DJ, Campbell F, Beyer FR, Mason J. Potassium supplementation for the management of primary hypertension in adults. *Cochrane Database Syst Rev.* 2006;3:CD004641.
 59. King DE. Dietary fiber, inflammation, and cardiovascular disease. *Mol Nutr Food Res.* 2005;49(6):594-600.
 60. Chu AJ. Antagonism by bioactive polyphenols against inflammation: a systematic view. *Inflamm Allergy Drug Targets.* 2014;13(1):34-64.
 61. Ning H, Van Horn L, Shay CM, Lloyd-Jones DM. Associations of dietary fiber intake with long-term predicted cardiovascular disease risk and C-reactive protein levels (from the National Health and Nutrition Examination Survey Data [2005-2010]). *Am J Cardiol.* 2014;113(2):287-291.
 62. Jiao J, Xu JY, Zhang W, Han S, Qin LQ. Effect of dietary fiber on circulating C-reactive protein in overweight and obese adults: a meta-analysis of randomized controlled trials. *Int J Food Sci Nutr.* 2015;66(1):114-119.
 63. Kaczmarczyk MM, Miller MJ, Freund GG. The health benefits of dietary fiber: beyond the usual suspects of type 2 diabetes mellitus, cardiovascular disease and colon cancer. *Metabolism.* 2012;61(8):1058-1066.
 64. McGill CR, Birkett A, Fulgoni Iii VL. Healthy Eating Index-2010 and food groups consumed by US adults who meet or exceed fiber intake recommendations NHANES 2001-2010. *Food Nutr Res.* 2016;60:29977.
 65. InterAct Consortium. Dietary fibre and incidence of type 2 diabetes in eight European countries: the EPIC-InterAct Study and a meta-analysis of prospective studies. *Diabetologia.* 2015;58(7):1394-1408.
 66. Dahl WJ, Stewart ML. Position of the academy of nutrition and dietetics: health implications of dietary fiber. *J Acad Nutr Diet.* 2015;115(11):1861-1870.